Interactions between antibiotics and antineoplastic drugs on antibacterial activity in vitro. 1990

R Henriksson, and S Holm, and B Littbrand
Department of Clinical Bacteriology, University Hospital, UmeƄ, Sweden.

The effects of various combinations of antibacterial (ampicillin, cephadroxil, doxycycline, imipenem, trimethoprimsulfadiazine) and antineoplastic (cisplatin, epirubicin, mitoxantrone) drugs were evaluated in vitro with regard to antibacterial activity on five clinical isolates from cancer patients of respectively Escherichia coli, Staphylococcus aureus and Streptococcus faecalis. With one exception no significant effects on the bacterial growth were observed in the presence of the antitumor drug alone. In contrast, all five strains of Strept. faecalis grew better when mitoxantrone was included in a concentration of 0.1 mg/l. A synergistic action between imipenem and mitoxantrone was seen for single strains of Staph. aureus and E. coli. Furthermore, a dose-effect related inhibition by cisplatin on the growth of Strept. faecalis in the presence of sub MIC levels of trimethoprimsulfadiazine was observed. The study indicates that interaction between antibacterial and antineoplastic drugs is an erratic phenomenon, which has to be dealt with separately for each combination of drugs as well as for each bacterial strain.

UI MeSH Term Description Entries
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D013293 Enterococcus faecalis A species of gram-positive, coccoid bacteria commonly isolated from clinical specimens and the human intestinal tract. Most strains are nonhemolytic. Streptococcus Group D,Streptococcus faecalis

Related Publications

R Henriksson, and S Holm, and B Littbrand
October 1977, Sovetskaia meditsina,
R Henriksson, and S Holm, and B Littbrand
February 1985, Cancer treatment reports,
R Henriksson, and S Holm, and B Littbrand
January 2009, HIV clinician,
R Henriksson, and S Holm, and B Littbrand
January 1976, Postepy higieny i medycyny doswiadczalnej,
R Henriksson, and S Holm, and B Littbrand
January 1978, Antibiotics and chemotherapy,
R Henriksson, and S Holm, and B Littbrand
January 1960, Trudy Instituta biologii,
R Henriksson, and S Holm, and B Littbrand
January 1980, Antibiotics and chemotherapy,
R Henriksson, and S Holm, and B Littbrand
January 1981, Postepy higieny i medycyny doswiadczalnej,
R Henriksson, and S Holm, and B Littbrand
January 2000, Mikrobiolohichnyi zhurnal (Kiev, Ukraine : 1993),
R Henriksson, and S Holm, and B Littbrand
February 2013, Nature reviews. Drug discovery,
Copied contents to your clipboard!